However, the rebate game played by drug manufacturers and pharmacy benefit managers in the U.S. limits optimal biosimilar competition. As a result, U.S. patient out-of-pocket costs are too high.

This agreement expands Teva’s partnership with Formycon, as they entered into an agreement in 2021 to commercialize FYB201, Formycon’s ranibizumab biosimilar in Europe, Canada, Israel ...